This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Death censored graft loss
Timeframe: 5 weeks
Decline in eGFR value over time
Timeframe: 5 weeks
Number of sessions received of Haemodialysis/Peritoneal Dialysis
Timeframe: 5 weeks
Number of patients receiving Nephrectomy
Timeframe: 5 weeks
Number of patients receiving re-transplantation
Timeframe: 5 weeks
Number of Hospital admissions per year overall
Timeframe: 5 weeks
Duration of hospital stay (including ICU) per year overall and by primary ICD-10 (ICD-9)/OPCS/HRG code
Timeframe: 5 weeks
Number of ICD-10 (ICD-9)/OPCS/HRG codes
Timeframe: 5 weeks
Number of A&E visits per year overall and by ICD-10 (ICD-9)/OPCS/HRG code
Timeframe: 5 weeks
Number of Outpatient visits per year overall and by ICD-10 (ICD-9)/OPCS/HRG code
Timeframe: 5 weeks
Duration and extent of Haemodialysis/Peritoneal dialysis per year
Timeframe: 5 weeks
Number of Treatments administered for chronic active AMR
Timeframe: 5 weeks
Cost of Hospital admissions (including ICU) per year overall and by ICD-10 (ICD-9)/OPCS/HRG
Timeframe: 5 weeks
Cost of A&E visits per year overall and by ICD-10(ICD-9)/OPCS/HRG
Timeframe: 5 weeks
Cost of Outpatient visits per year overall and by ICD-10 (ICD-9)/OPCS/HRG
Timeframe: 5 weeks
Cost of Treatment administered for chronic active AMR per year
Timeframe: 5 weeks
Cost of re-starting Haemodialysis/Peritoneal dialysis per year
Timeframe: 5 weeks
Cost of nephrectomy
Timeframe: 5 weeks
Cost of re-transplantations
Timeframe: 5 weeks